FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof
US8962556B2 · kind B2 · utility
14Cited by
25References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 7, 2007 |
| Grant date | Feb 24, 2015 |
| Priority date | — |
| Expiry date | Sep 19, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides that include a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding the polypeptides, compositions of the same and methods for use thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.